REGISTER RECORD · clinicaltrials.gov
NCT02203643
Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
AS THE REGISTER RECORDS IT
Status and dates
| Status as listed | COMPLETED: completed |
|---|---|
| Register last updated | 2026-04-14 |
| Retrieved by this site | 2026-10-03 |
| Source | https://clinicaltrials.gov/study/NCT02203643 |
What this record shows
This entry describes research activity. It is not a statement about market authorisation, and it is not regulatory, legal or medical advice: a trial being listed, completed or halted says nothing about whether a substance may be sold or used anywhere. Status wording is reproduced as the register writes it and is never mapped onto a simpler vocabulary.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.